Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 10/20 | 0.65 |
| ▸ | BRAF | P15056 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452584 | 0.91 | RIPK1 (0.64) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL12333868 | 0.90 | BRAF (0.63) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2452667 | 0.87 | BRAF (0.65) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2454632 | 0.86 | BRAF (0.70) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2456245 | 0.84 | BRAF (0.64) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2455436 | 0.83 | BRAF (0.64) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2452470 | 0.82 | BRAF (0.69) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2455839 | 0.81 | BRAF (0.64) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2453182 | 0.80 | RIPK1 (0.80) | RIPK1RIPK3BRAFKDR | |
| SCHEMBL2452555 | 0.80 | KDR (0.71) | RIPK1RIPK3BRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399921-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-08-12 | — | — | EP | disclosed |
| US-8697874-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2399921-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-12-28 | — | — | EP | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237620-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NR3C2, RAF1 | RIPK1 991/4885RIPK3 705/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.